{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T01:04:27Z","timestamp":1780016667644,"version":"3.53.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hemagglutinin (HA), one of the main surface glycoproteins of the influenza virus, is essential for viral entry into host cells. Antibodies targeting HA can neutralize the virus, offering protection against infection. HA-specific antibody titers are therefore key markers of immune protection and vaccine efficacy. However, data on humoral immune responses to influenza A(H3N2) and influenza A(H1N1)pdm09 and viruses in India remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>Laboratory-confirmed influenza specimens from 2016 to 2017 were analyzed in this retrospective longitudinal study. A systematic random sampling method was used to obtain 160 paired serum samples, distributed among four distinct age groups. Hemagglutination inhibition (HAI) assays were performed to assess the antibody responses against influenza A(H3N2) and influenza A(H1N1)pdm09 viruses following natural infection. Additionally, preexisting antibodies and antibodies to heterologous influenza strains were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following natural infection, seroconversion rates were 77.1% for individuals infected with influenza A(H3N2) and 84.9% for those infected with influenza A(H1N1). Preexisting antibodies were detected in 40.8% of the acute-phase influenza A(H3N2) samples and 17% of the acute-phase influenza A(H1N1)pdm09 samples. Antibodies to heterologous strains were also detected in both groups, particularly between influenza A(H1N1)pdm09 and influenza A(H3N2), as well as with influenza B lineages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results of this study show that most of the study population had evidence of immunity against both influenza A(H3N2) and influenza A(H1N1) virus strains. Evidence of antibodies to other influenza strains was also observed in a few samples, thus emphasizing the need for continuous monitoring and tailored vaccination strategies in India.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12985-026-03146-w","type":"journal-article","created":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T06:16:32Z","timestamp":1775369792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of pre and postinfection immunity to the hemagglutinin proteins of Influenza A(H1N1)pdm09 and Influenza A(H3N2) in India: a retrospective longitudinal study"],"prefix":"10.1186","volume":"23","author":[{"given":"Anup","family":"Jayaram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"M.T.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Varamballi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavitha","family":"Karunakaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Malsane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudheesh","family":"N.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujwal","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naren Babu","family":"N.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiranjay","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anitha","family":"Jagadesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,5]]},"reference":[{"key":"3146_CR1","volume-title":"Fields Virology. Fields virology","author":"PF Wright","year":"2007","unstructured":"Wright PF, Neumann G, Kawaoka Y, Orthomyxoviruses. Fields Virology. Fields virology. Philadelphia, PA, USA: Lippincott-Williams & Wilkins; 2007."},{"key":"3146_CR2","unstructured":"World Health Organization. Influenza (seasonal) [Internet]. Geneva: World Health Organization; [cited 2025 Nov 17]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal)."},{"issue":"1","key":"3146_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/vaccines3010022","volume":"3","author":"MR Sandbulte","year":"2015","unstructured":"Sandbulte MR, Spickler AR, Zaabel PK, Roth JA. Optimal use of vaccines for control of influenza A virus in Swine. Vaccines. 2015;3(1):22\u201373. https:\/\/doi.org\/10.3390\/vaccines3010022.","journal-title":"Vaccines"},{"issue":"19","key":"3146_CR4","doi-asserted-by":"publisher","first-page":"S2238","DOI":"10.21037\/jtd.2017.12.122","volume":"10","author":"D Hermans","year":"2018","unstructured":"Hermans D, Webby RJ, Wong SS. Atypical antibody responses to influenza. J Thorac Dis. 2018;10(19):S2238-47. https:\/\/doi.org\/10.21037\/jtd.2017.12.122.","journal-title":"J Thorac Dis"},{"issue":"1","key":"3146_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1172\/JCI44947","volume":"121","author":"DM Tscherne","year":"2011","unstructured":"Tscherne DM, Garc\u00eda-Sastre A. Virulence determinants of pandemic influenza viruses. J Clin Invest. 2011;121(1):6\u201313. https:\/\/doi.org\/10.1172\/JCI44947.","journal-title":"J Clin Invest"},{"issue":"6","key":"3146_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","volume":"19","author":"F Krammer","year":"2019","unstructured":"Krammer F. The human antibody response to influenza A virus infection and vaccination. Nat Rev Immunol. 2019;19(6):383\u201397. https:\/\/doi.org\/10.1038\/s41577-019-0143-6.","journal-title":"Nat Rev Immunol"},{"key":"3146_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/546274","volume":"2014","author":"M Khanna","year":"2014","unstructured":"Khanna M, Sharma S, Kumar B, Rajput R. Protective immunity based on the conserved hemagglutinin stalk domain and its prospects for universal influenza vaccine development. BioMed Res Int. 2014;2014:546274. https:\/\/doi.org\/10.1155\/2014\/546274.","journal-title":"BioMed Res Int"},{"issue":"16","key":"3146_CR8","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/s0264-410x(03)00071-9","volume":"21","author":"C Gerdil","year":"2003","unstructured":"Gerdil C. The annual production cycle for influenza vaccine. Vaccine. 2003;21(16):1776\u20139. https:\/\/doi.org\/10.1016\/s0264-410x(03)00071-9.","journal-title":"Vaccine"},{"issue":"5682","key":"3146_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1126\/science.1097211","volume":"305","author":"DJ Smith","year":"2004","unstructured":"Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus ADME, et al. Mapping the antigenic and genetic evolution of influenza virus. Science. 2004;305(5682):371\u20136. https:\/\/doi.org\/10.1126\/science.1097211.","journal-title":"Science"},{"key":"3146_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01677","volume":"10","author":"HO Padilla-Quirarte","year":"2019","unstructured":"Padilla-Quirarte HO, Lopez-Guerrero DV, Gutierrez-Xicotencatl L, Esquivel-Guadarrama F. Protective Antibodies Against Influenza Proteins. Front Immunol. 2019;10. https:\/\/doi.org\/10.3389\/fimmu.2019.01677.","journal-title":"Front Immunol"},{"issue":"5","key":"3146_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3390\/v11050405","volume":"11","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Xu C, Zhang H, Liu GD, Xue C, Cao Y. Targeting hemagglutinin: approaches for broad protection against the influenza A virus. Viruses. 2019;11(5):405. https:\/\/doi.org\/10.3390\/v11050405. (PubMed PMID: 31052339; PubMed Central PMCID: PMC6563292).","journal-title":"Viruses"},{"key":"3146_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054890","author":"EGW Huijskens","year":"2013","unstructured":"Huijskens EGW, Reimerink J, Mulder PGH, van Beek J, Meijer A, de Bruin E, et al. Profiling of humoral response to influenza A(H1N1)pdm09 infection and vaccination measured by a protein microarray in persons with and without history of seasonal vaccination. PLoS ONE. 2013. https:\/\/doi.org\/10.1371\/journal.pone.0054890.","journal-title":"PLoS ONE"},{"issue":"3","key":"3146_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4103\/ijmr.IJMR_407_18","volume":"147","author":"L Kant","year":"2018","unstructured":"Kant L, Guleria R. Pandemic Flu, 1918: After hundred years, India is as vulnerable. Indian J Med Res. 2018;147(3):221\u20134. https:\/\/doi.org\/10.4103\/ijmr.IJMR_407_18.","journal-title":"Indian J Med Res"},{"key":"3146_CR14","unstructured":"Govindakarnavar A. Manipal [Internet]. [cited 2026 Mar 8]. Hospital based surveillance of Acute Febrile Illness in India. Available from:"},{"key":"3146_CR15","first-page":"139","volume-title":"Manual for the laboratory diagnosis and virological surveillance of influenza","author":"World Health Organization, editor","year":"2011","unstructured":"World Health Organization, editor. Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva: World Health Organization; 2011. p. 139."},{"key":"3146_CR16","unstructured":"WHO reagent kit for. identification and characterization of influenza viruses [Internet]. [cited 2021 Dec 8]. Available from: http:\/\/influenzacentre.org\/documents\/publications_reports\/reagent_kit_2017.pdf"},{"issue":"7","key":"3146_CR17","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3201\/eid1807.111680","volume":"18","author":"M Baz","year":"2012","unstructured":"Baz M, Papenburg J, Hamelin ME, Ouakki M, Skowronski DM, De Serres G, et al. Seroconversion to seasonal influenza viruses after A(H1N1)pdm09 virus infection, Quebec, Canada. Emerg Infect Dis. 2012;18(7):1132\u20134. https:\/\/doi.org\/10.3201\/eid1807.111680.","journal-title":"Emerg Infect Dis"},{"key":"3146_CR18","unstructured":"World Health Organization. Serological diagnosis of influenza by microneutralization assay [Internet]. Geneva; [cited 2025 Nov 17]. Available from: https:\/\/www.who.int\/publications\/i\/item\/serological-diagnosis-of-influenza-by-microneutralization-assay"},{"key":"3146_CR19","unstructured":"WHO Expert Committee on Biological Standardization. Annex 9 \u2013 Guidelines for influenza vaccine quality [Internet]. [cited 2026 Mar 8]. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/prequal\/vaccines\/who-trs-1004-web-annex-9.pdf"},{"issue":"1","key":"3146_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-12727-y","volume":"12","author":"JE Hernandez-Davies","year":"2022","unstructured":"Hernandez-Davies JE, Dollinger EP, Pone EJ, Felgner J, Liang L, Strohmeier S, et al. Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants. Sci Rep. 2022;12(1):9198. https:\/\/doi.org\/10.1038\/s41598-022-12727-y.","journal-title":"Sci Rep"},{"key":"3146_CR21","doi-asserted-by":"publisher","first-page":"D45","DOI":"10.1016\/j.vaccine.2008.07.066","volume":"26","author":"AS Monto","year":"2008","unstructured":"Monto AS. Epidemiology of influenza. Vaccine. 2008;26:D45-8. https:\/\/doi.org\/10.1016\/j.vaccine.2008.07.066.","journal-title":"Vaccine"},{"key":"3146_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02332-17","author":"F Krammer","year":"2018","unstructured":"Krammer F, Fouchier RAM, Eichelberger MC, Webby RJ, Shaw-Saliba K, Wan H, et al. NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines? mBio. 2018. https:\/\/doi.org\/10.1128\/mbio.02332-17.","journal-title":"mBio"},{"issue":"6","key":"3146_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad244","volume":"10","author":"MK Andrew","year":"2023","unstructured":"Andrew MK, Pott H, Staadegaard L, Paget J, Chaves SS, Ortiz JR, et al. Age differences in comorbidities, presenting symptoms, and outcomes of influenza illness requiring hospitalization: a worldwide perspective from the Global Influenza Hospital Surveillance Network. Open Forum Infect Dis. 2023;10(6):ofad244. https:\/\/doi.org\/10.1093\/ofid\/ofad244.","journal-title":"Open Forum Infect Dis"},{"key":"3146_CR24","doi-asserted-by":"publisher","unstructured":"Bahadoran A, Lee SH, Wang SM, Manikam R, Rajarajeswaran J, Raju CS et al. Immune Responses to Influenza Virus and Its Correlation to Age and Inherited Factors. Front Microbiol [Internet]. 2016 [cited 2023 Jul 16];7. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fmicb.2016.01841","DOI":"10.3389\/fmicb.2016.01841"},{"issue":"5","key":"3146_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1089\/vim.2019.0010","volume":"32","author":"CSH Alladi","year":"2019","unstructured":"Alladi CSH, Jagadesh A, Prabhu SG, Arunkumar G. Hemagglutination inhibition antibody response following influenza A(H1N1)pdm09 virus natural infection: a cross-sectional study from Thirthahalli, Karnataka, India. Viral Immunol. 2019;32(5):230\u20133. https:\/\/doi.org\/10.1089\/vim.2019.0010.","journal-title":"Viral Immunol"},{"issue":"19","key":"3146_CR26","doi-asserted-by":"publisher","DOI":"10.2807\/ese.17.19.20170-en","volume":"17","author":"K Waalen","year":"2012","unstructured":"Waalen K, Kilander A, Dudman SG, Ramos-Ocao R, Hungnes O. Age-dependent prevalence of antibodies cross-reactive to the influenza A(H3N2) variant virus in sera collected in Norway in 2011. Euro Surveill. 2012;17(19):20170. https:\/\/doi.org\/10.2807\/ese.17.19.20170-en.","journal-title":"Euro Surveill"},{"issue":"10","key":"3146_CR27","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.vaccine.2019.01.055","volume":"37","author":"JG Petrie","year":"2019","unstructured":"Petrie JG, Martin ET, Truscon R, Johnson E, Cheng CK, McSpadden EJ, et al. Evaluation of correlates of protection against influenza A(H3N2) and A(H1N1)pdm09 infection: applications to the hospitalized patient population. Vaccine. 2019;37(10):1284\u201392 (.055 PubMed PMID: 30738647; PubMed Central PMCID: PMC6595494).","journal-title":"Vaccine"},{"key":"3146_CR28","unstructured":"Middle-aged individuals. may be in a perpetual state of H3N2 influenza virus susceptibility | Nature Communications [Internet]. [cited 2022 Jun 29]. Available from: https:\/\/www.nature.com\/articles\/s41467-020-18465-x"},{"key":"3146_CR29","unstructured":"Cross-Reactive Antibody Responses to the. 2009 Pandemic H1N1 Influenza Virus | New England Journal of Medicine [Internet]. [cited 2026 Mar 8]. Available from: https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa0906453?url_ver=Z39.88-2003\ud52f_id=ori:rid:crossref.org\ud52f_dat=cr_pub%20%200www.ncbi.nlm.nih.gov"},{"key":"3146_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.antiviral","volume":"114","author":"MS Ahmed","year":"2015","unstructured":"Ahmed MS, Jacques LC, Mahallawi W, Ferrara F, Temperton N, Upile N, et al. Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection. Antiviral Res. 2015;114:106\u201312. https:\/\/doi.org\/10.1016\/j.antiviral. .2014.12.008 PubMed PMID: 25513756.","journal-title":"Antiviral Res"},{"key":"3146_CR31","unstructured":"World Health Organization. Recommended composition of influenza virus vaccines for use in the 2016\u20132017 northern hemisphere influenza season [Internet]. [cited 2025 Nov 17]. Available from: https:\/\/www.who.int\/publications\/m\/item\/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2016-2017-northern-hemisphere-influenza-season"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03146-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03146-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03146-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:37:41Z","timestamp":1780015061000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-026-03146-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,5]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3146"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03146-w","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,5]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The rights and welfare of all the study participants were protected throughout the study, and their involvement contributed meaningfully to the diagnosis and treatment of the disease. Ethical clearance for this study was granted by the Institutional Ethics Committee of Manipal Academy of Higher Education (IEC No: EC\/001\/2021). All experiments were performed in compliance with ethical standards and relevant institutional and national guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent to publish has been obtained from the contributing authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}